Bessemer Venture Partners and Bain & Company published their joint benchmark report, The 2026 Healthcare AI ROI Scorecard , surveying 226 healthcare C-suite executives across 65 discrete use cases spanning health systems, commercial payers, and biopharma enterprises.

The multi-year transformation has compressed rapidly: while 84% of healthcare executives in 2025 expected generative AI to transform treatment decisions within three to five years, 71% confirm it already has in 2026.

Financial payback is arriving twice as fast as originally underwritten: enterprise buyers modeled a 24-month horizon, yet realized a material return within ~12 months, generating an average 3.5x return on investment (ROI) and exceeding initial financial underwriting in roughly 40% of deployed use cases (with 54% seeing material ROI within year one).

Rather than relying on soft satisfaction surveys or speculative multi-year projections, the 2026 Scorecard tracks realized return multiples on deployed capital:

Provider Revenue Cycle Management (RCM): Delivers a 4.0x realized ROI, with 67% of solutions operating as semi- or fully autonomous agents. Value is primarily driven by faster speed to output, increased net revenue capture, and direct labor efficiencies.

Payer Claims Operations: Generates a 3.4x realized ROI, powered by direct FTE reductions and accelerated claims turnaround times.

Pharma Preclinical Discovery: Posts a 3.4x realized ROI, driven by frontier model efficiency gains across target identification and molecular screening pipelines.

Payer Provider Network Management: Achieves a 3.3x realized ROI, primarily through accelerated credentialing timelines and automated directory maintenance.

2x realized ROI, with 62% of solutions deployed as semi- or fully autonomous agents that handle digital navigation and inbound call deflection.

Source link